Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.
Trian Comments on Solventum’s Sale of its Purification & Filtration Business
Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current profit as part of Solventum, with much of that improvement driven by lower allocated costs.
As tariffs loom, 3M-spinoff Solventum’s operating margins are continuing to shrink while its investors look toward the ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Reports Q4 revenue $2.074B, consensus $2.05B. “Solventum (SOLV) executed another quarter of solid performance, enabling us to deliver full year ...
The Maplewood, Minnesota-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, were $1.41 per share. The results topped Wall Street expectations.
Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...
Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41 Generated ...
Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback